2009
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer
Mayer EL, Partridge AH, Harris LN, Gelman RS, Schumer ST, Burstein HJ, Winer EP. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Research And Treatment 2009, 117: 615-623. PMID: 19294501, PMCID: PMC4578795, DOI: 10.1007/s10549-009-0366-5.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerStable diseaseValidation cohortBreast cancerSequential cohortsPhase ICombination oral therapyOral antineoplastic therapyDays on/7Primary endpointSecondary endpointsOral therapyPartial responseAntineoplastic therapySerious toxicityDose reductionDrug dosesM2/dayCohortSignificant toxicityPatientsTherapyMTDCycle 1Capecitabine
2002
Adherence to Therapy With Oral Antineoplastic Agents
Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to Therapy With Oral Antineoplastic Agents. Journal Of The National Cancer Institute 2002, 94: 652-661. PMID: 11983753, DOI: 10.1093/jnci/94.9.652.Peer-Reviewed Original ResearchConceptsOral antineoplastic agentsAntineoplastic agentsOral antineoplastic therapyOral anticancer agentsAssessment of adherenceStudy of adherencePrediction of adherenceImplementation of interventionsChemotherapy recommendationsOral medicationsPrescribed regimensClinical outcomesPatient adherencePediatric populationAdherence ratesPoor adherenceAntineoplastic therapyAdherence issuesClinical trialsCancer preventionPhysician's officeAdherence behaviorAvailable evidenceAdherenceCertain populations